Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Mtor pathway expression as potential predictive biomarker in patients with advanced neuroendocrine tumors treated with everolimus

Academic Article
Publication Date:
2020
Short description:
Mtor pathway expression as potential predictive biomarker in patients with advanced neuroendocrine tumors treated with everolimus / Gelsomino, F., Casadei-Gardini, A., Caputo, F., Rossi, G., Bertolini, F., Petrachi, T., Spallanzani, A., Pettorelli, E., Kaleci, S., Luppi, G.. - In: CANCERS. - ISSN 2072-6694. - 12:5(2020), p. 1201. [10.3390/cancers12051201]
abstract:
Background. Everolimus (Eve), which is a mammalian target of Rapamicin (mTOR) inhibitor, is part of the therapeutic armamentarium of neuroendocrine tumors (NETs). Currently, there are no validated biomarkers predicting Eve efficacy in NETs. In this study, we explore whether the expression of phosphorilated (p)-mTOR and p70S6-kinase (S6K), a downstream effector of mTOR, correlates with the outcome of patients with NET that were treated with Eve. Methods. Tissue specimens that were derived from NETs treated with Eve at our Institution were examined for the expression levels of p-mTOR and p-S6K by immunohistochemistry. Response rate (RR), progression-free survival (PFS), and overall survival (OS) were analyzed in two groups: p-mTOR/p-S6K positive (group 1) and p-mTOR/p-S6K negative (group 2). Univariate and multivariate Cox regression analysis were performed. Results. Twenty-four patients with advanced NETs that were treated with Eve were included in the analysis. Eight out 24 (33.3%) patients were both p-mTOR and p-S6K positive. A better median PFS and OS in group 1 (18.2 and 39.9 months) as compared to group 2 (13 and 32.4 months) was depicted, with a toxicity profile that was comparable with data literature. Conclusions. Our study suggests that the activation of mTOR pathway can predict better outcomes in patients with NET treated with Eve. However, these results warrant further confirmation in a prospective setting.
Iris type:
1.1 Articolo in rivista
Keywords:
Everolimus; MTOR inhibitor; Neuroendocrine tumors; Prognosis; Survival prediction
List of contributors:
Gelsomino, F.; Casadei-Gardini, A.; Caputo, F.; Rossi, G.; Bertolini, F.; Petrachi, T.; Spallanzani, A.; Pettorelli, E.; Kaleci, S.; Luppi, G.
Authors of the University:
CASADEI GARDINI ANDREA
Handle:
https://iris.unisr.it/handle/20.500.11768/107546
Published in:
CANCERS
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0